Docoh
Loading...

GSK Glaxosmithkline

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK stock data

(
)

Calendar

12 Mar 21
18 Apr 21
Quarter (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
17 Feb 21 Glaxosmithkline Common Stock Buy Aquire P Yes No 18 150,000 2.7M 1,183,663
17 Feb 21 Glaxosmithkline Common Stock Conversion Aquire C Yes No 0 327,852 0 1,033,663
17 Feb 21 Glaxosmithkline Common Stock Conversion Aquire C Yes No 0 247,324 0 705,811
17 Feb 21 Glaxosmithkline Common Stock Conversion Aquire C Yes No 0 458,487 0 458,487
17 Feb 21 Glaxosmithkline Series D Preferred Stock Common Stock Conversion Dispose C Yes No 0 1,737,619 0 0
17 Feb 21 Glaxosmithkline Series C Preferred Stock Common Stock Conversion Dispose C Yes No 0 3,125,000 0 0
17 Feb 21 Glaxosmithkline Series A Preferred Stock Common Stock Conversion Dispose C Yes No 0 7,119,850 0 0
24 Jul 20 Glaxosmithkline Common Stock Buy Aquire P Yes No 2.25 1,260,504 2.84M 4,626,389
24 Jul 20 Glaxosmithkline Warrant Common Stock Buy Aquire P Yes No 0.125 1,260,504 157.56K 1,260,504
21 Jul 20 Glaxosmithkline Common Stock Buy Aquire P Yes No 18 361,111 6.5M 2,248,304

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

12.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 784 796 -1.5%
Opened positions 112 76 +47.4%
Closed positions 124 86 +44.2%
Increased positions 234 236 -0.8%
Reduced positions 327 323 +1.2%
13F shares
Current Prev Q Change
Total value 11.08B 11.15B -0.6%
Total shares 301.11M 296.39M +1.6%
Total puts 2.68M 1.79M +49.2%
Total calls 2.03M 1.95M +4.0%
Total put/call ratio 1.3 0.9 +43.5%
Largest owners
Shares Value Change
Dodge & Cox 62.94M $2.32B +39.9%
FMR 19.36M $712.49M -2.0%
Capital International Investors 17.62M $648.41M +6.7%
TROW T. Rowe Price 16.55M $608.9M -6.4%
Fisher Asset Management 16.53M $608.18M +1.9%
RY Royal Bank Of Canada 14.71M $541.39M -5.5%
Renaissance Technologies 14.27M $525.19M -22.1%
Hotchkis & Wiley Capital Management 10.36M $381.37M +40.0%
STT State Street 9.51M $354.62M +1.3%
Black Creek Investment Management 7.44M $273.91M +14.8%
Largest transactions
Shares Bought/sold Change
Dodge & Cox 62.94M +17.94M +39.9%
Renaissance Technologies 14.27M -4.06M -22.1%
Arrowstreet Capital, Limited Partnership 7.26M +3.29M +83.0%
Camber Capital Management 3.5M +3.05M +677.8%
Hotchkis & Wiley Capital Management 10.36M +2.96M +40.0%
American Century Companies 39.74K -2.8M -98.6%
Rockefeller Capital Management 123.59K -2.69M -95.6%
BAC Bank Of America 3.4M -2.27M -40.0%
FHI Federated Hermes 0 -2.25M EXIT
Nuveen Asset Management 2.33M +2.09M +891.0%
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: adherence, adolescent, adult, Advil, Agency, agile, albuterol, analyze, Annex, antibiotic, attack, attractive, augment, automated, automation, Avolve, ban, Bancroft, behavior, beneficial, Benlysta, Bexsero, Blenrep, bond, Boostrix, carefully, chronic, classic, climate, Cloud, complement, Contac, court, Crispr, CureVac, daprodustat, deployment, Digestive, diligence, disagree, disease, disguised, Dovato, drew, Duvroq, dynamic, EC, EHS, elongated, embracing, empower, Encepur, energy, erode, extremely, feedback, feladilimab, final, Flonase, Flovent, fourth, hacking, harmonization, hospital, IBA, importantly, imposition, indefinite, inequality, Infanrix, inhibitor, intensive, interconnected, interconnectivity, Intercontinental, Juluca, Justice, kidney, learning, legitimacy, lifted, linkage, loan, machine, macroeconomic, medium, Menveo, modern, month, myeloma, nasal, nitrosamine, Nucala, occasionally, OECD, optimize, otilimab, Otrivin, outperform, paediatric, Panadol, panel, PARP, partially, Pediarix, pharmacovigilance, posed, premium, presence, presumption, prioritization, prioritized, pronounced, protectionism, quickly, Rabipur, ransomware, recoverable, refractory, regimen, relapsed, Relenza, repercussion, resilience, rest, resurgence, rooted, Scop, seize, Sensodyne, social, solicit, sophisticated, sought, Specialty, standalone, Sterile, streamline, strength, summarize, summarized, synergy, temporarily, Theraflu, timeline, Tivicay, traditional, Transderm, Trelegy, tuition, turn, twelve, undermine, understood, unfavorable, unique, unknown, unregulated, urgent, variable, Ventolin, vir, water, weak, week, worsened, Zejula
Removed: aid, analyse, andBoostrix, andTivicay, asserted, background, Beecham, commercialisation, Cooperation, coverage, cybersecurity, defendant, determination, Ebola, Ellipta, erosion, evident, frequently, GDPR, geographical, Glaxo, inappropriate, incremental, inherently, inInternal, Insufficient, integral, intent, interaction, labelling, measurable, media, merged, method, misuse, newer, November, ofBenlysta, ofSeretide, older, outbreak, outsourced, phasing, predecessor, preventing, procured, publishing, punitive, pursuit, remeasurement, replacing, side, SmithKline, solution, spread, storm, summarise, sustainability, therapeutic, Theravance, unanticipated, unauthorised, unpredictable, Wellcome, widely

Proxies

No filings